6 results about "Intermediate cell" patented technology

The application discloses a novel dye-sensitized solar cell optimization method, and relates to the technical field of semiconductor devices, and comprises the following steps: on the basis of a dye-sensitized solar cell model, first, the material of a hole transport layer of the dye-sensitized solar cell model is changed, a plurality of first cell models are obtained correspondingly, and performance simulation is performed; based on the performance simulation result, an intermediate cell model is selected from the plurality of first cell models; then, the electrode material of the intermediate cell model is changed, a plurality of second cell models are obtained correspondingly, and performance simulation is performed; based on the performance simulation result, a to-be-adjusted cell model is selected from the plurality of second cell models; finally, a plurality of adjustable parameters of the to-be-adjusted cell model are optimized, and a target cell model is obtained. Through optimization of the material of the hole transport layer, the material of the electrode and the numerical value of part of the adjustable parameters of the dye-sensitized solar cell model, the performance of a solar cell corresponding to the dye-sensitized solar cell model can be improved.

The invention discloses a preparation method and application of renal progenitor cells. The method specifically comprises the following steps: inducing pluripotent stem cells to be differentiated into an intermediate mesoderm cell stage through a GSK-3alpha / beta inhibitor, and inducing cells in the intermediate mesoderm cell stage to be differentiated into a cap-like mesenchymal stage by using a nuclear receptor agonist containing FGF-2 and RAR / RXR, so as to obtain the renal progenitor cells with obvious specific characteristics and potentials of the cap-like mesenchymal. According to the method, the high-purity and high-quality renal progenitor cells can be obtained without separation and purification, the purity can reach 99.9%, and the obtained renal progenitor cells have the differentiation potential of kidney-like organs, basically have no PSCs residues, have the differentiation potential of kidney-like organs and are suitable for clinical cell therapy; and the operation is simple, stable and controllable, and safe, effective, high-purity and homogeneous renal progenitor cells can be prepared on a large scale.

The invention relates to an energy storage device (1) for storing electrical energy for a motor vehicle (14), comprising several stacked storage cells (3), preferably prismatic storage cells (3). An intermediate cell layer (2) is arranged between each pair of adjacent storage cells (3). The intermediate cell layer has a spacer (4) and a compression element (5), preferably a compression pad, wherein the spacer (4) has a higher thermal conductivity and a lower compressibility compared to the compression element (5). The compression element (5) is dimensioned and arranged relative to the spacer (4) such that at least one side (6) of the spacer (4), which faces one of the two adjacent storage cells (3), is completely covered by the compression element (5). The invention further relates to a motor vehicle (14) comprising such an energy storage device (1).

One embodiment of the semiconductor device comprises a first circuit cell and a second circuit cell, the latter adjoining the first circuit cell at an intermediate cell boundary. The first circuit cell has one or more first conductive traces in a first metallization region of a first metallization layer and has one or more first vias beneath the first metallization layer. The second circuit cell has one or more second conductive traces in a second metallization region of the first metallization layer and has one or more second vias beneath the first metallization layer. The first metallization region and the second metallization region are spaced apart by a common space and extend along the cell boundary.The one or more first via structures and the one or more second via structures are located within an area with a zigzag structure along the cell boundary.

The invention relates to a culture method of TIL from pleural effusion and / or ascites. Specifically, the invention provides the in-vitro culture method of the pleural effusion and / or ascites derived TIL, and the method comprises the following steps: 1) obtaining TIL seed cells from pleural effusion and / or ascites, and 2) sorting the TIL seed cells to obtain intermediate cells which are CD45RA-cells, CD39 + cells, or CD45RA-CD39 + cells.

Systems and methods for secure portals between virtual worlds are provided. In some embodiments, the systems and methods include deploying a secure portal between two virtual worlds. This is performed by rendering a top cell for a first virtual world. Rendering includes a transparent region overlapping a portal. Then an intermediate cell is layered underneath the top cell. This intermediate cell comprises the portal. A message is received from the top cell. The message includes a minimum rendering size, shape and at least one transform. This message is transferred to a bottom cell for a second virtual world, where it is rendered (in part) responsive to the message. The top cell, the intermediate cell and the bottom cell are then layered to generate a scene. In some embodiments, the rendered portion of the bottom cell comports to the minimum rendering size, and the intermediate cell is transparent. In some cases, the cells are either iFrames, or separate applications.